Profound Medical Corp.

Profound Medical Corp. is a commercial-stage medical device company specializing in the development and marketing of AI-powered, MRI-guided, incision-free therapeutic systems for the ablation of diseased tissue. Headquartered in Mississauga, Ontario, Canada, the company's mission is to deliver precise, customizable treatments that effectively target disease while prioritizing the preservation of patients' quality of life.

The company's flagship product is the TULSA-PRO system, designed for the treatment of prostate diseases, including prostate cancer, benign prostatic hyperplasia (BPH), and localized radio-recurrent prostate cancer. This technology integrates real-time Magnetic Resonance Imaging (MRI), robotically-driven transurethral ultrasound, and closed-loop temperature feedback control to enable precise and customizable tissue ablation. Additionally, Profound Medical commercializes Sonalleve, an innovative therapeutic platform that combines real-time MRI and thermometry for applications such as the treatment of uterine fibroids and the palliative pain treatment of bone metastases.

Led by Chairman and CEO Dr. Arun Menawat, Profound Medical continues to advance its technology and market presence. Recent developments include the reporting of Q1 2024 financial results on May 9, 2024, and Q4 2023 results on March 7, 2024. The company also announced positive outcomes from its CAPTAIN trial, which compared the TULSA Procedure to robotic radical prostatectomy, demonstrating significant improvements in the preservation of erectile function and urinary continence. Furthermore, Profound Medical received U.S. FDA 510(k) clearance for its TULSA-AI® Contouring Assistant module, enhancing treatment planning capabilities. The company is actively expanding its global reach through strategic distribution agreements.